Thyroid eye disease following administration of the BNT162B2 COVID-19 vaccine.

Fujita, H; Makino, S; Hasegawa, T; Saima, Y; Tanaka, Y; Nagashima, S; Kakehashi, A; Kaburaki, T

Fujita, H; Makino, S; Hasegawa, T; Saima, Y; Tanaka, Y; Nagashima, S; Kakehashi, A; Kaburaki, T.

Afiliación

Fujita H; From the Department of Ophthalmology, Saitama Medical Center Jichi Medical University, Saitama-shi, Saitama-ken, Japan.
Makino S; Inoda Eye Clinic, Nasushiobara-shi, Tochigi-ken, Japan.
Hasegawa T; Department of Ophthalmology, Jichi Medical University, Shimotsuke-shi, Tochigi-ken, Japan.
Saima Y; From the Department of Ophthalmology, Saitama Medical Center Jichi Medical University, Saitama-shi, Saitama-ken, Japan.
Tanaka Y; Division of Ophthalmology, Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan.
Nagashima S; From the Department of Ophthalmology, Saitama Medical Center Jichi Medical University, Saitama-shi, Saitama-ken, Japan.
Kakehashi A; Department of Endocrinology and Metabolism, Saitama Medical Center Jichi Medical University, Saitama-shi, Saitama-ken, Japan.
Kaburaki T; From the Department of Ophthalmology, Saitama Medical Center Jichi Medical University, Saitama-shi, Saitama-ken, Japan.

QJM ; 116(2): 130-132, 2023 Feb 24.

Article en En | MEDLINE | ID: mdl-36448695

Asunto(s)

COVID-19; Oftalmopatía de Graves; Humanos; Vacuna BNT162; Vacunas contra la COVID-19

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_doencas_transmissiveis Asunto principal: Oftalmopatía de Graves / COVID-19 Límite: Humans Idioma: En Revista: QJM Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google